trial

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)

NCTId NCT04738123
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 256 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2022-11-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
256 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2021-04-06
Primary completion
2022-11-29
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Investigators

1
Inder Kaul, MDStudy Director

Sites

32 total
Bentonville, United StatesLittle Rock, United StatesAnaheim, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesLong Beach, United StatesOrange, United StatesSan Diego, United StatesHollywood, United StatesHollywood, United StatesAtlanta, United States

Linked catalysts

1
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized — primary completion2022-11-29

Facts & assertions

4 sourced
Enrollment
256
Phase
PHASE3
Primary Completion Date
2022-11-29
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia; Psychosis
indication
Schizophrenia
indication
investigator
Inder Kaul, MD
person